Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Pearl Therapeutics

Explore full profile

Develops a combination of products for the treatment of respiratory diseases, including chronic obstructive pulmonary disease

Redwood City, United StatesFounded 2006Biotech & Life Sciences
Valuation $100–500M Latest valuation · 2013
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Pearl Therapeutics and the history behind them.

About Pearl Therapeutics

Pearl Therapeutics, a subsidiary of AstraZeneca, specializes in developing innovative respiratory therapies aimed at improving patient outcomes. Operating in the pharmaceutical and biotechnology market, Pearl Therapeutics focuses on creating advanced inhalation technology for the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The company serves healthcare providers and patients, leveraging its expertise in drug formulation and delivery systems to offer effective treatment options. Pearl Therapeutics generates revenue through the development and commercialization of its proprietary respiratory therapies, often in collaboration with its parent company, AstraZeneca. The business model includes research and development, clinical trials, regulatory approvals, and market distribution. By addressing unmet medical needs in respiratory care, Pearl Therapeutics aims to enhance the quality of life for patients worldwide.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2006
Headquarters
Redwood City, United States
Employees
53
Open positions
None listed
Dealroom signal
31.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Respiratory, Pulmonary, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b
Links
WebsiteLinkedIn

Latest news

Press, funding announcements and product moves mentioning Pearl Therapeutics.

See all news

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Jun 2013 $1.2B — AstraZeneca —
LATE VCOther financing Apr 2013 $42M $167M New Leaf Venture Partners · 5AM Ventures · Clarus Ventures · Vatera Healthcare Partners —
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Pearl Therapeutics website traffic

Latest recorded traffic for Pearl Therapeutics is 110 monthly website visits. Pearl Therapeutics's team declined 29.3% over the past year.

Latest monthly visits110 1-year team growth-29.3%
Monthly website visitsApr 2016–Jul 2023
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Verona PharmaFirst-in-class inhaled therapies for chronic respiratory diseases London, United Kingdom Acquired 149 $95M $10B
Hawkeye BioA new preventive screening paradigm for lung cancer Torrance, United States Operational
Beyond AirDeveloping nitric oxide therapy products to improve lung function Kokhav Ya'ir Tsur Yig'al, Israel Operational
ArtiQHas developed AI-based software to help doctors save time and improve interpretation of lung function tests and diagnosis of lung diseases Leuven, Belgium Acquired
Spyryx BiosciencesSpyryx Biosciences is developing next generation therapeutics for obstructive lung diseases Durham, United States Closed
VapothermDevelops and manufactures innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders Exeter, United Kingdom Acquired
PulmocideFocused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract London, United Kingdom Operational
branded.meGuerrilla Ventures, a Delhi-based angel fund, was founded in 2013 by Dr Ritesh Malik San Francisco, United States Acquired
Showing 8 of the closest matchesCompare every metric →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • New Leaf Venture Partners
  • Nektar Therapeutics

Series B and later5 investors entered at this stage

  • Oxford Finance
  • Standard Treasury
  • Vatera Healthcare Partners
  • 5AM Ventures
  • Clarus Ventures

Other known investors1 additional known investor

  • AstraZeneca

Talent

Book a demo to see the people
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Redwood City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Pearl Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pearl Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.